PrEP Eligibility Based on HIV Status
Determine HIV status and patient’s eligibility for PrEP using this flowchart.
Determine HIV status and patient’s eligibility for PrEP using this flowchart.
Diagnose, treat, and prevent community acquired pneumonia using key recommendations from the IDSA/ATS CAP guidelines.
The FDA has approved Fetroja® (cefiderocol; Shionogi) for the treatment of adult patients with HABP/VABP caused by susceptible Gram-negative pathogens.
Researchers compared HAdV-3 with HAdV-7 replication kinetics and host response in ex vivo human lung tissue cultures.
There is a low incidence of second PJI in patients with bacteremia or hematogenous periprosthetic joint infection with concomitant prosthetic implants.
As SARS-CoV-2 has spread around the world, major health disparities have become apparent among patients with COVID-19, particularly in the Hispanic/Latinx community.
Investigators assessed patients who hospitalized with microbial S aureus bacteremia to determine the most meaningful cutoff point to define S aureus persistent bacteremia.
Researchers sought to determine whether individuals recovered from mildly symptomatic COVID-19 develop and sustain immunological memory against the SARS-CoV-2 virus.
Investigators analyzed a potential link between community-acquired Staphylococcus aureus bloodstream infection and increased short-term risk for myocardial infarction, which is associated with subsequent mortality.
The otic suspension is a combination of ciprofloxacin, a fluoroquinolone antibacterial and dexamethasone, a corticosteroid.